<DOC>
	<DOC>NCT00144599</DOC>
	<brief_summary>This is a double-blind, Phase III study to evaluate the efficacy, safety and PK of MRA in patients with sJIA.</brief_summary>
	<brief_title>Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Juvenile</mesh_term>
	<criteria>Inclusion criteria Patients diagnosed as having systemic JIA based on the International League of Associations for Rheumatology criteria (1997) Patients between 2 and 19 years of age Patients who are under 16 years of age at onset Patients who have been treated with corticosteroids (continued treatment for 3 months or longer at a dose of â‰¥0.2 mg/kg as prednisolone equivalent) but who failed to respond adequately or in whom treatment could not be continued or the dose could not be increased due to adverse drug reactions Exclusion criteria Patients who have been treated with infliximab or etanercept within 12 weeks before treatment with the investigational product Patients who have received the following treatments within 4 weeks before treatment with the investigational product 1. Surgical treatment (e.g., operation) 2. Plasma exchange therapy"</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>